natgillin/translations-raw huggingface dataset:
Mekanisme: Øget dasabuvireksponering skyldes muligvis gemfibrozils CYP2C8hæmning, og øget paritaprevireksponering skyldes muligvis gemfibrozils OATP1B1hæmning. 
Increase in dasabuvir exposure is possibly due to CYP2C8 inhibition and increase in paritaprevir possibly due to OATP1B1 inhibition by gemfibrozil.
Viekirax 12,5 mg / 75 mg / 50 mg filmovertrukne tabletter 
Viekirax 12.5 mg/75 mg/50 mg film-coated tablets
24 uger. 
24 weeks
Hver æske indeholder 56 tabletter (multipakning med 4 æsker a hver 14 tabletter). 
Each carton contains 56 tablets (multipack carton containing 4 inner cartons of 14 tablets each).
Viekirax og dasabuvir + RBV i 12 uger n/N % 95 %-KI 
Viekirax and dasabuvir with RBV for 12 weeks n/N % 95% CI
Paritaprevir hæmmer de hepatiske uptake-transportere OATP1B1 og OATP1B3, og paritaprevir og ritonavir hæmmer OATP2B1. 
Paritaprevir is an inhibitor of the hepatic uptake transporters OATP1B1 and OATP1B3, and paritaprevir and ritonavir are inhibitors of OATP2B1.
In vitro-studier har vist, at ombitasvir, paritaprevir og ritonavir ikke hæmmer den organiske kationtransporter (OCT2), den organiske aniontransporterer (OAT3) eller multilægemiddel- og toksinekstrusionsproteinerne (MATE1 og MATE2K) ved klinisk relevante koncentrationer. 
In vitro studies show that ombitasvir, paritaprevir, and ritonavir are not inhibitors of organic cation transporters (OCT2), organic anion transporters (OAT3), or multidrug and toxin extrusion proteins (MATE1 and MATE2K) at clinically relevant concentrations.
Hos 18 GT1aog GT4-inficerede patienter blev Viekirax med eller uden dasabuvir også undersøgt uden ribavirin; der blev ikke set anæmi-bivirkninger hos disse patienter. 
Viekirax with or without dasabuvir was also evaluated without ribavirin in 18 GT1a- and GT4-infected patients; no adverse events of anaemia were seen in these subjects.
Samtidig administration af Viekirax med eller dasabuvir sammen med lægemidler, der er substrater af BCRP, kan øge plasmakoncentrationen af disse substrater og nødvendiggøre dosisjustering/klinisk overvågning. 
Co-administration of Viekirax with or without dasabuvir together with medicinal products that are substrates of BCRP may increase plasma concentrations of these transporter substrates, potentially requiring dose adjustment/clinical monitoring.
Behandling med atazanavir plus Viekirax uden dasabuvir anbefales ikke (↑ 
Treatment with atazanavir + Viekirax without dasabuvir is not recommended-(↑ paritaprevir).
• fusidinsyre 
• fusidic acid
Persistensen af paritaprevir-, ombitasvir- og dasabuvir-resistensrelaterede aminosyresubstitutioner i henholdsvis NS3, NS5A og NS5B blev undersøgt hos genotype 1a-smittede forsøgspersoner i fase 2bstudier. 
The persistence of paritaprevir, ombitasvir, and dasabuvir resistance-associated amino acid substitutions in NS3, NS5A, and NS5B, respectively, was assessed in genotype 1a-infected subjects in Phase 2b trials.
Det anbefales at afbryde behandlingen med pitavastatin/fluvastatin midlertidigt, så længe Viekirax-behandlingen pågår. 
A temporary suspension of pitavastatin/fluvastatin is recommended for the duration of treatment with Viekirax.
Koncentrationen af tacrolimus eller sirolimus i helblod bør overvåges ved initiering og under samtidig administration med Viekirax og dasabuvir og dosis og/eller doseringshyppighed bør justeres efter behov. 
Tacrolimus or sirolimus whole blood concentrations should be monitored upon initiation and throughout co-administration with Viekirax and dasabuvir and the dose and/or dosing frequency should be adjusted as needed.
Darunavir 800 mg én gang dagligt kan bruges i kombination med Viekirax og dasabuvir, hvis administration er på samme tid, og der ikke er udtalt PI-resistens (nedsat darunavir-eksponering). 
Darunavir, dosed 800 mg once daily, if administered at the same time as Viekirax and dasabuvir, can be used in the absence of extensive PI resistance (darunavir exposure lowered).
CALCIUMANTAGONISTER Amlodipin 
CALCIUM CHANNEL BLOCKERS Amlodipine
↑ repaglinid 
↑ repaglinide
Det anbefales at afbryde behandlingen med fluvastatin og pitavastatin midlertidigt, så længe Viekirax-behandlingen pågår. 
A temporary suspension of fluvastatin and pitavastatin is recommended for the duration of treatment with Viekirax.
Samtidig administration af Viekirax med eller uden dasabuvir og lægemidler, der er stærke hæmmere af CYP3A4, forventes at øge paritaprevir plasmakoncentration og må derfor ikke administreres samtidig med Viekirax (se pkt. 
Co-administration of Viekirax with or without dasabuvir with medicinal products that are strong inhibitors of CYP3A4 is expected to increase paritaprevir plasma concentrations and must not be co-administered with Viekirax (see section 4.5).
Genotype 1b, uden cirrose eller med kompenseret cirrose 
Genotype 1b, without cirrhosis or with compensated cirrhosis
Samlet SVR12 HCV genotype 1a HCV genotype 1b Resultat for patienter uden SVR12 VF under behandlinga Recidiv Andetb a. Bekræftet HCV ≥ 25 IE/ml efter HCV-rna < 25 IE/ml under behandling, bekræftet 1 log10 IE/ml stigning i HCV-rna fra nadir eller HCV-rna vedvarende ≥ 25 IE/ml efter mindst 6 ugers behandling. 
Overall SVR12 HCV genotype 1a HCV genotype 1b Outcome for subjects without SVR12 On-treatment VFa Relapse Otherb a. Confirmed HCV ≥ 25 IU/mL after HCV RNA < 25 IU/mL during treatment, confirmed 1 log10 IU/mL increase in
PEARL III - genotype 1b, behandlingsnaive, uden cirrose Design: 
PEARL-III - genotype 1b, treatment-naïve, without cirrhosis Design:
Ciclosporin 100 mg doseret alene, 10 mg administreret sammen med Viekirax og 30 mg administreret sammen med Viekirax med dasabuvir. 
Ciclosporin 100 mg dosed alone, 10 mg administered with Viekirax and 30 mg administered with Viekirax + dasabuvir.
Der bør udvises forsigtighed. 
Caution is advised.
Viekirax er kontraindiceret hos patienter med moderat til svært nedsat leverfunktion (Child-Pugh B eller C) (se pkt. 
Viekirax is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C) (see sections 4.3 and 5.2).
↑ dabigatran etexilat 
↑ dabigatran etexilate
Klinisk kommentar dasabuvir 
Clinical Comments without dasabuvir
Tabel 20. 
Table 20.
Følgende dasabuvirbehandlingsrelaterede varianter i NS5B blev observeret hos 34 forsøgspersoner: M414T, G554S, S556G, G558R eller D559G/N. 
Dasabuvir treatment-emergent variants M414T, G554S, S556G, G558R or D559G/N in NS5B were observed in 34 subjects.
• prikbladet perikon (hypericum perforatum) 
• St. John's Wort (Hypericum perforatum)
2 mg enkeltdosis7 
2 mg single dose7
I genotype 1a reducerede substitutionerne F43L, R155K, A156T og D168A/H/V/Y i HCV-NS3 følsomheden over for paritaprevir. 
In genotype 1a, substitutions F43L, R155K, A156T, and D168A/F/H/V/Y in HCV NS3 reduced susceptibility to paritaprevir.
Oral anvendelse Tag to tabletter om morgenen 
Take two tablets in the morning
Amiodaron, disopyramid, dronedaron mod uregelmæssig hjerterytme astemizol, terfenadin mod allergisymptomer - fås i håndkøb atorvastatin, lovastatin, simvastatin, lomitapid mod forhøjet kolesterol carbamazepin, phenytoin, phenobarbital mod epilepsi cisaprid til lindring af visse maveproblemer clarithromycin, fusidinsyre, rifampicin, telithromycin mod bakterieinfektioner colchicin hos patienter, som har alvorlige problemer med deres lever eller nyrer mod urinsyregigt conivaptan til normalisering af natrium i blodet efavirenz, etravirin, lopinavir/ritonavir, saquinavir, tipranavir, nevirapin, indinavir, cobicistat mod hiv-infektion apalutamid, enzalutamid mod prostatakræft ergotamin, dihydroergotamin mod migræne ergonovin, methylergometrin i forbindelse med fødsler ethinyløstradiol-holdige lægemidler som f.eks. de fleste p-piller og p-ringe som prævention itraconozol, ketoconazol, posaconazol, voriconazol mod svampeinfektioner midazolam, triazolam (når de tages gennem munden) 
These medicines may be available without a prescription atorvastatin, lovastatin, simvastatin, lomitapide to lower blood cholesterol carbamazepine, phenytoin, phenobarbital for epilepsy cisapride for relieving certain stomach problems clarithromycin, fusidic acid, rifampicin, telithromycin for bacterial infections colchicine in patients who have severe problems with their liver or kidneys for treating gout attacks conivaptan for making the sodium levels in the blood normal efavirenz, etravirine, lopinavir/ritonavir, saquinavir, tipranavir, nevirapine, indinavir, cobicistat for HIV infection apalutamide,enzalutamide for prostate cancer ergotamine, dihydroergotamine for migraine headaches ergonovine, methylergometrine used in childbirth ethinyloestradiol-containing medicines such as those contained in most contraceptive pills and vaginal rings used for contraception for contraception itraconozole, ketoconozole, posaconazole, voriconazole for fungal infections midazolam, triazolam (when taken by mouth) for anxiety or trouble sleeping mitotane for symptoms of malignant tumours of the adrenal glands pimozide, lurasidone for schizophrenia quetiapine for schizophrenia, bipolar disorder and major depressive disorder quinidine for abnormal heart rhythms or malaria ranolazine for chronic angina (chest pain)
Selvom dosisjustering af digoxin ikke er nødvendig, anbefales det at overvåge 
While no dose adjustment is necessary for digoxin, appropriate monitoring of serum digoxin levels is ombitasvir
Paritaprevirs gennemsnitlige EC50-værdi mod replikoner indeholdende NS3 fra et panel af behandlingsnaive genotype 1a- og 1b-isolater i HCV-replikoncellekulturanalysen var henholdsvis 0,86 nM (interval: 0,43-1,87 nM; n = 11) og 0,06 nM (interval: 0,030,09 nM; n = 9). 
The mean EC50 of paritaprevir against replicons containing NS3 from a panel of treatment-naïve genotype 1a and 1b isolates in the HCV replicon cell culture assay was 0.86 nM (range 0.43 to 1.87 nM; n=11) and 0.06 nM (range 0.03 to 0.09 nM; n=9), respectively.
Dosisnormaliserede sirolimus -ratioer er vist for interaktion med Viekirax + dasabuvir. 
Dose normalized sirolimus ratios are shown for interaction with Viekirax + dasabuvir.
Viekirax og dasabuvir med/eller uden ribavirin i 12 eller 24 uger N = 200a 
Viekirax and dasabuvir with/without ribavirin for 12 or 24 Weeks N = 200a
200 mg én gang dagligt/ 300 mg én gang dagligt 
200 mg once daily/300 mg once daily
Det anbefales at nedsætte colchicin-dosen eller afbryde colchicinbehandlingen hos patienter med normal nyre- og leverfunktion, hvis behandling med Viekirax med eller uden dasabuvir er nødvendig. 
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with Viekirax with or without dasabuvir is required.
PEARL II - genotype 1b, pegIFN + RBV-erfarne, uden cirrose 
PEARL-II - genotype 1b, pegIFN+RBV-experienced, without cirrhosis
Til patienter med genotype 4-infektion anbefales Viekirax i kombination med ribavirin. 
Viekirax in combination with ribavirin is recommended in genotype 4 infection.
Brug af glukokortikoider sammen med Viekirax, navnlig i længere tid, må kun finde sted, hvis de potentielle fordele opvejer risikoen for systemiske glukokortikoid-bivirkninger (se pkt. 
Concomitant use of Viekirax and glucocorticoids, particularly long-term use, should only be initiated if the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.5).
salmeterol mod astma sildenafil mod forhøjet blodtryk i lungekredsløbet ("pulmonal arteriel hypertension") 
salmeterol for asthma sildenafil when used to treat a heart and lung disorder called “pulmonary arterial hypertension”
Viekirax og dasabuvir i 8 uger 
Viekirax and dasabuvir for 8 weeks
I genotype 1b reducerede substitutionerne L28T, L31F/V samt Y93H alene eller i kombination med L28M, R30Q, L31F/M/V eller P58S i HCV-NS5A følsomheden over for ombitasvir. 
In genotype 1b, substitutions L28T, L31F/V, as well as Y93H alone or in combination with L28M, R30Q, L31F/M/V or P58S in HCV NS5A reduced susceptibility to ombitasvir.
Ethinyløstradiol er kontraindiceret i kombination med Viekirax (se pkt. 
Ethinyloestradiol is contraindicated in combination with Viekirax (see sections 4.3 and 4.4).
I alle de kliniske studier med ombitasvir, paritaprevir og ritonavir blev forsøgslægemidlet administreret sammen med mad. 
All clinical trials with ombitasvir, paritaprevir and ritonavir have been conducted following administration with food.
Pakningsstørrelser a 56 tabletter (multipakning med 4 æsker, som hver indeholder 14 tabletter). 
Pack-size of 56 tablets (multipack carton containing 4 inner cartons of 14 tablets each).
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig. 
Tell your doctor or pharmacist if you are taking, have recently taken and before starting any other medicines.
HCV genotype 1b Viekirax og dasabuvir 
HCV Genotype 1b Viekirax and dasabuvir
I del 1b blev alle forsøgspersoner behandlet med Viekirax og dasabuvir med ribavirin i 12 uger. 
In Part 1b, all subjects received Viekirax and dasabuvir with ribavirin for 12 weeks.
Geometrisk gennemsnit af Cmax og AUC for multiple doser af Viekirax 150 mg/100 mg/25 mg én gang dagligt i kombination med dasabuvir 250 mg to gange dagligt sammen med mad hos raske forsøgspersoner 
Geometric mean Cmax, AUC of multiple doses of Viekirax 150 mg/100 mg/25 mg once daily with dasabuvir 250 mg twice daily with food in healthy volunteers
Mekanisme: Øget paritaprevireksponering kan skyldes lopinavirs og den højere ritonavirdosis' hæmning af CYP3A/ efflukstransportere. 
Mechanism: Increase in paritaprevir exposures may be due to inhibition of CYP3A/efflu x transporters by lopinavir and higher dose of ritonavir
Den daglige rosuvastatindosis må højst være 10 mg (se pkt. 
The maximum daily dose of rosuvastatin should be 10 mg (see section 4.4).
Ombitasvirs gennemsnitlige EC50-værdi mod replikoner indeholdende NS5A fra et panel af behandlingsnaive genotype 1a- og 1b-isolater i HCV-replikoncellekulturanalysen var henholdsvis 0,66 pM (interval: 0,35-0,88 pM; n = 11) og 1,0 pM (interval: 0,741,5 pM; n = 11). 
The mean EC50 of ombitasvir against replicons containing NS5A from a panel of treatment-naïve genotype 1a and 1b isolates in the HCV replicon cell culture assay was 0.66 pM (range 0.35 to 0.88 pM; n=11) and 1.0 pM (range 0.74 to 1.5 pM; n=11), respectively.
De behandlede patienter (N = 68) havde en median alder på 58 år (interval: 32-77 år); 83,8% var mænd; 58,8% var sorte; 73,5% af patienterne var inficeret med HCV GT1a; 75,0 % havde CKD-stadium 5 og 69,1% var i hæmodialyse. 
Treated subjects (N=68) had a median age of 58 years (range: 32-77 years); 83.8% were male; 58.8% were Black; 73.5% of subjects were infected with HCV GT1a; 75.0%% had Stage 5 CKD and 69.1% were on haemodialysis.
Lægemidler, der hæmmer CYP3A4 
Medicinal products that inhibit CYP3A4
Tacrolimus 2 mg doseret alene, 0,5 mg administreret sammen med Viekirax og 2 mg administreret sammen med Viekirax + dasabuvir. 
Tacrolimus 2 mg was dosed alone, 0.5 mg administered with Viekirax and 2 mg was administered with Viekirax + dasabuvir.
Bivirkninger, der er set ved Viekirax i kombination med dasabuvir med eller uden ribavirin 
Adverse drug reactions identified with Viekirax in combination with dasabuvir with and without ribavirin
↔ ombitasvir/paritaprevir/dasabuvir (baseret på en sammenligning på tværs af studier) 
NA ↔ ombitasvir/paritaprevir/dasabuvir (based on the crossstudy comparison)
Samtidig brug af Viekirax og fluticason navnlig i længere tid, må kun finde sted, hvis de potentielle fordele opvejer risikoen for systemiske glukokortikoidbivirkninger (se pkt. 
Concomitant use of Viekirax and fluticasone particularly long-term use, should only be initiated if the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
Det er ikke nødvendigt at justere dosis af Viekirax hos patienter med let, moderat eller svært nedsat nyrefunktion eller hos patienter i dialyse med nyresygdom i slutstadiet (se pkt. 
No dose adjustment of Viekirax is required for patients with mild, moderate, or severe renal impairment, or end-stage-renal disease on dialysis (see section 5.2).
Viekirax 12,5 mg / 75 mg / 50 mg tabletter ombitasvir / paritaprevir / ritonavir 
Viekirax 12.5 mg / 75 mg / 50 mg tablets ombitasvir / paritaprevir / ritonavir
Oral anvendelse Tag to tabletter om morgenen. 
Take two tablets in the morning.
↑ itraconazol ↑ posaconazol ↑ paritaprevir ↑ dasabuvir 
↑ itraconazole ↑ posaconazole ↑ paritaprevir ↑ dasabuvir
ANTIVIRALT MIDDEL MOD HEPATITIS C-VIRUS Sofosbuvir 
HCV ANTIVIRALS Sofosbuvir
Viekirax er indiceret i kombination med andre lægemidler til behandling af kronisk hepatitis C (CHC) hos voksne (se pkt. 
Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).
Der bør udvises forsigtighed og reduktion af dosis kan være nødvendig for repaglinid ved samtidig administration med Viekirax med eller uden dasabuvir 
Caution should be used and dose decrease maybe needed for repaglinide when administered with Viekirax with or without dasabuvir.
Det anbefales ikke at bruge Viekirax som monoterapi; Viekirax skal bruges i kombination med andre lægemidler til behandling af hepatitis C-infektion (se pkt. 
Viekirax is not recommended for administration as monotherapy and must be used in combination with other medicinal products for the treatment of hepatitis C infection (see sections 4.2 and 5.1).
Samtidig brug af efavirenz er kontraindiceret (se pkt. 
Concomitant use with efavirenz is contraindicated (see section 4.3).
Nifedipin Mekanisme: Hæmning af CYP3A4 
Nifedipine Mechanism: CYP3A4 inhibition
Det er ikke undersøgt, hvilken betydning tidligere ombitasvir-, paritaprevir- eller dasabuvir-behandling har for effekten af andre NS5A-hæmmere, NS3/4A-proteasehæmmere eller NS5Bhæmmere. 
The impact of prior ombitasvir, paritaprevir or dasabuvir treatment experience on the efficacy of other NS5A inhibitors, NS3/4A protease inhibitors, or NS5B inhibitors has not been studied.
I del 2 blev alle forsøgspersoner med HCV GT1 behandlet med Viekirax og dasabuvir med eller uden ribavirin i 12 eller 24 uger. 
In Part 2, subjects with HCV GT1 received Viekirax and dasabuvir with or without ribavirin for 12 or 24 weeks.
Resistens over for paritaprevir og ombitasvir fremkaldt af varianter i henholdsvis NS3 og NS5A udvalgt i cellekultur blev fænotypisk karakteriseret i genotype 4a. 
In genotype 4a, resistance to paritaprevir or ombitasvir by variants in NS3 or NS5A, respectively, selected in cell culture were phenotypically characterised.
Klinisk monitorering og dosisjustering kan være nødvendig for smephenytoin. 
Clinical monitoring and dose adjustment maybe needed for s-mephenytoin.
På basis af farmakokinetiske populationsanalyser af data fra kliniske fase 3-studier vil en stigning eller et fald på 10 år i alder fra 54 år (median alder i fase 3-studierne) medføre en ændring på < 10 % i eksponeringen for ombitasvir og ≤ 20% ændring i eksponering for paritaprevir. 
Based on population pharmacokinetic analysis of data from Phase 3 clinical studies, a 10 year increase or decrease in age from 54 years (median age in the Phase 3 studies) would result in approximately 10%
800/100 mg én gang dagligt 
800/100 mg once daily
I genotype 1a reducerede substitutionerne M28T/V, Q30E/R, L31V, H58D, Y93C/H/N og M28V + Q30R i HCV-NS5A følsomheden over for ombitasvir. 
In genotype 1a, substitutions M28T/V, Q30E/R, L31V, H58D, Y93C/H/N, and M28V + Q30R in HCV NS5A reduced susceptibility to ombitasvir.
Dosisjustering er ikke nødvendig for for carisoprodol; øgning af dosis, hvis klinisk indiceret ombitasvir 
NA No dose adjustment required for carisoprodol; increase dose if clinically indicated.
Levertransplanterede forsøgspersoner med GT4-infektion blev doseret med Viekirax med RBV (uden cirrose i 12 uger [n = 2] og med cirrose i 24 uger [n = 1]. 
Subjects with liver transplant and GT4 infection were dosed with Viekirax with RBV (non-cirrhotic for 12 weeks [n=2] and cirrhotic for 24 weeks [n=1].
Tabel 19. 
Table 19.
• hvis du tager et eller flere af de lægemidler, der er angivet i nedenstående tabel, da der kan opstå alvorlige eller livstruende virkninger, hvis Viekirax tages sammen med disse lægemidler. 
This is because serious or lifethreatening effects can occur when Viekirax is taken with these medicines.
Der sås ingen forsøgsrelaterede bivirkninger med paritaprevir, ritonavir og ombitasvir. 
No study related adverse reactions with paritaprevir, ritonavir, or ombitasvir were observed.
SAPPHIRE I - genotype 1, behandlingsnaive, uden cirrose 
SAPPHIRE-I - genotype 1, treatment-naïve, without cirrhosis
SVR12 for peginterferon+ribavirin-erfarne genotype 1-smittede forsøgspersoner i SAPPHIRE II 
SVR12 for genotype 1-infected peginterferon+ribavirin-experienced subjects in SAPPHIRE-II
− hvis du bemærker, at din mave svulmer op. 
− Notice swelling of your stomach area
Samtidig brug af Viekirax og dasabuvir er kontraindiceret (se pkt. 
NA Concomitant use of Viekirax with dasabuvir is contraindicated (see section 4.3).
Tabel 2 viser indvirkningen på koncentrationen af Viekirax med eller uden dasabuvir og samtidigt administrerede lægemidler baseret på mindste kvadraters gennemsnit (90 %-konfidensinterval). 
Table 2 provides the Least Squares Means Ratio (90% Confidence Interval) effect on concentration of Viekirax with or without dasabuvir and concomitant medicinal products.
Hvis det er klinisk indiceret, skal der bruges højere doser omeprazol ombitasvir 
NA If clinically indicated higher doses of omeprazole should be used.
TURQUOISE-III: behandlingsnaive eller pegIFN + RBV-erfarne med kompenseret cirrose Design: 
TURQUOISE-III: treatment-naïve or pegIFN + RBV-experienced with compensated cirrhosis Design:
Hos forsøgspersoner med let nedsat leverfunktion var gennemsnitlig Cmax og AUC for paritaprevir, ritonavir og ombitasvir henholdsvis 29-48 %, 34-38 % og op til 8 % lavere end hos forsøgspersoner med normal leverfunktion. 
In subjects with mild hepatic impairment, paritaprevir, ritonavir and ombitasvir mean Cmax and AUC values decreased by 29% to 48%, 34% to 38% and up to 8%, respectively, compared to subjects with normal hepatic function.
Sådan skal du tage Viekirax 4. 
How to store Viekirax 6.
Farmakokinetikken for kombinationen af ombitasvir 25 mg, paritaprevir 200 mg og ritonavir 100 mg med dasabuvir 400 mg blev undersøgt hos non-HCV inficerede patienter med let nedsat leverfunktion (ChildPugh A), moderat nedsat leverfunktion (Child-Pugh B) og svært nedsat leverfunktion (Child-Pugh C). 
Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 200 mg, and ritonavir 100 mg, with dasabuvir 400 mg were evaluated in non-HCV infected subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment.
Bemærk: Følgende varianter blev selekteret i cellekultur, men var ikke behandlingsrelaterede: NS3varianter: A156T hos genotype 1a samt R155Q og D168H hos genotype 1b. NS5A-varianter: Y93C/H 
Note: The following variants were selected in cell culture but were not treatment-emergent: NS3 variants A156T in genotype 1a, and R155Q and D168H in genotype 1b; NS5A variants Y93C/H in genotype 1a, and L31F/V or Y93H in combination with L28M, L31F/V or P58S in genotype 1b; and NS5B variants Y448H in genotype 1a, and M414T and Y448H in genotype 1b.
prikbladet perikon (hypericum perforatum) 
St. John's Wort (hypericum perforatum)
ANTIKONVULSIVE MIDLER Carbamazepin 
ANTICONVULSANTS Carbamazepine
Farmakokinetikken for kombinationen af ombitasvir 25 mg, paritaprevir 200 mg og ritonavir 100 mg blev ikke undersøgt hos patienter med let nedsat leverfunktion (Child-Pugh A), moderat nedsat leverfunktion (Child-Pugh B) og svært nedsat leverfunktion (Child-Pugh C). 
Pharmacokinetics of the combination of ombitasvir 25 mg, paritaprevir 200 mg, and ritonavir 100 mg were not evaluated in subjects with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (ChildPugh C) hepatic impairment.
Viekirax med dasabuvir atazanavir ombitasvir paritaprevir 
Viekirax + dasabuvir atazanavir ombitasvir paritaprevir